


THE POWER OF PLUS WITH PURAPLY® XT

Native, cross-linked extracellular matrix scaffold + sustained antimicrobial effectiveness within the product to support wound healing and aid in granulation tissue formation¹⁻⁴



I PuraPly®XT


FIVE-LAYER NATIVE ECM

- Provides a scaffold for cellular migration and proliferation⁵
- Contains more cross-linked collagen* to resist degradation⁶
- Maximizes surface area for enhanced PHMB saturation^{1,3,7}




BROAD-SPECTRUM PHMB

- Proactively disrupts bioburden^{1,3,8}
- Demonstrates high tissue compatibility and low cytotoxicity^{2,8,9}



EXTRA-FENESTRATED

- Enables coverage over irregularly-shaped wounds with one-directional conformity
- Allows exudate to flow freely through the device




* Compared to PuraPly® AM
ECM=extracellular matrix; PHMB=polyhexamethylene biguanide

SCIENTIFIC EVIDENCE

ANTIMICROBIAL EFFECTIVENESS WITHIN PURAPLY XT^{2,†}

>99%

MRSA reduction from post-debridement baseline




^aP<0.05 vs pre- and post-debridement baseline; ^bP<0.05 vs Aquacel Ag and PriMatrix Ag; ^cP<0.05 vs BlastX; ^dP<0.05 vs pre-debridement baseline

Data shown compared MRSA (methicillin-resistant *Staphylococcus aureus*) colonies in each wound, using a porcine deep reticular dermal wound model

PURAPLY XT LOW CYTOTOXICITY^{2,†}

>94%

Fibroblast viability at 48 hours




^aP<0.001 vs Blast X

Data shown measured cell proliferation and cell viability using human dermal fibroblasts in media conditioned with test materials

[†] In a study evaluating the antimicrobial effectiveness within PuraPly AM and PuraPly XT versus a variety of other wound products

PURAPLY® XT HELPS YOU MANAGE A WIDE VARIETY OF WOUNDS¹



* Abrasions, lacerations, second-degree burns, skin tears

† Donor sites/grfts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence

INDICATIONS & USAGE

- PuraPly XT is a native, cross-linked extracellular matrix scaffold with sustained antimicrobial effectiveness to resist microbial colonization within the product and reduce microbes penetrating through it¹
- PuraPly XT is intended for the management of acute and chronic wounds¹
- PuraPly XT should be applied post-debridement and overexpansion should be avoided to ensure prescribed product application
- PuraPly XT will naturally be resorbed into the wound and is not intended to be removed¹

Product Number	Description/Dimensions	Total Size (cm ²)	Billable Units	HCPCS Code	UPC Number
515-071	PURAPLYAM XT-COM 4.91X4.91 EXTRA FENESTRATED	24.10	25	Q4197	618474000466

References: **1.** PuraPly XT [package insert]. Canton, MA: Organogenesis Inc; 2023. **2.** Davis SC, et al. *Int Wound J*. 2022;19(1):86-99. **3.** Brantley J, et al. *Wounds Int*. 2016;7(3):1-5. **4.** Bain MA, et al. *J Comp Eff Res*. 2020;9(10):691-703. **5.** Data on file. PDR-0008. Organogenesis Inc. **6.** Data on file. PX_DR-0002. Organogenesis Inc. **7.** Carpenter S, et al. *Wounds*. 2016;28(6 suppl):S1-S20. **8.** Gilbert P, et al. *J Appl Microbiol*. 2005;99(4):703-715. **9.** Hübner NO, et al. *Skin Pharmacol Physiol*. 2010;23(1 suppl):17-27.

